Neuroprotection in cerebral ischemia: Emphasis on the SAINT trial.
In: Current Cardiology Reports, Jg. 10 (2008), Heft 1, S. 37-42
Online
academicJournal
Zugriff:
Acute ischemic stroke (AIS) is a significant cause of death and disability in the United States. It has been 10 years since tissue plasminogen activator became the first medication approved by the US Food and Drug Administration for treatment for AIS. However, this treatment simply reopens arteries. The identification of deleterious cellular reactions that occur secondary to cerebral ischemia has led investigators to search for neuroprotection strategies to complement reperfusion. More than 100 human trials, including a handful of phase III trials, had failed to produce an efficacious neuroprotective agent. In 2006, the first positive trial of neuroprotection was published: the SAINT I (Stroke-Acute Ischemic NXY Treatment) study. In February 2008, the SAINT II study was published, indicating that NXY-059 was not effective for AIS treatment. [ABSTRACT FROM AUTHOR]
Copyright of Current Cardiology Reports is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Neuroprotection in cerebral ischemia: Emphasis on the SAINT trial.
|
---|---|
Autor/in / Beteiligte Person: | Chacon, Marcus ; Jensen, Matt ; Sattin, Justin ; Zivin, Justin |
Link: | |
Zeitschrift: | Current Cardiology Reports, Jg. 10 (2008), Heft 1, S. 37-42 |
Veröffentlichung: | 2008 |
Medientyp: | academicJournal |
ISSN: | 1523-3782 (print) |
DOI: | 10.1007/s11886-008-0008-2 |
Sonstiges: |
|